Cencora, Inc. has entered into a definitive agreement to acquire EyeSouth Partners’ retina business for $1.1Bn. The agreement, announced on March 23, 2026, provides for the affiliated retina physicians of EyeSouth Partners to join Cencora’s Retina Consultants of America (RCA) — the largest network of retina centers in the United States. While the transaction is subject to customary regulatory approvals, it marks a significant expansion of Cencora’s management services organization (MSO) and its overall footprint in specialty healthcare.
Strategic Rationale: Cencora
The acquisition is a direct extension of Cencora’s strategy to build high-margin specialty services capabilities adjacent to its core pharmaceutical distribution business. Cencora has argued consistently that investment in specialty support assets enhances the long-term economics of its core operations, particularly in ophthalmology, where drug distribution and clinical services are tightly interlinked. The EyeSouth transaction deepens that thesis by expanding the physician base within RCA, increasing the network’s geographic reach and strengthening its clinical trial infrastructure.
Cencora acquired an 85% interest in RCA for approximately $4.6Bn in early 2025, establishing its position in retina care. That investment has since demonstrated meaningful returns. The EyeSouth acquisition at $1.1Bn represents a considerably smaller bolt-on acquisition that leverages the existing RCA platform without requiring significant incremental infrastructure investment. Management expects the transaction to be slightly accretive to adjusted diluted earnings per share in the first twelve months following close, net of financing costs. Cencora reaffirmed its fiscal 2026 financial guidance on announcement, noting that the current guidance does not contemplate the EyeSouth transaction closing within the fiscal year.
Asset Profile: EyeSouth Partners
EyeSouth Partners is an Atlanta-based physician management group focused on ophthalmology and retina care. Operating as a portfolio company of Olympus Partners, EyeSouth has utilized an “affiliate-and-expand” model to build a regional network of specialists while maintaining clinical autonomy. This transaction is a strategic corporate carve-out: Cencora is acquiring only the retina-specific portion of EyeSouth’s business, leaving the broader ophthalmology platform intact under its existing ownership.
Upon closing, EyeSouth’s affiliated retina physicians will integrate into the RCA Management Services Organization (MSO) framework. This transition provides these specialists with immediate access to RCA’s extensive clinical trial network — which currently oversees 75 active site studies — and its advanced research and innovation capabilities. This move allows the affiliated physicians to scale their patient care through expanded research access, while Cencora strengthens its density in the specialized retina market.
Sector Context: Specialty Care Consolidation
The Cencora-EyeSouth transaction reflects a well-established pattern in healthcare M&A: large pharmaceutical distribution and services companies moving up the value chain into specialty care management. Cencora and its peers have embraced dealmaking for high-margin specialty care services as a structural priority, with cancer care networks, ophthalmology and rare disease management emerging as the primary consolidation targets. The logic is consistent across these deals — specialty care requires coordinated drug procurement, patient monitoring and clinical infrastructure that distributor-affiliated MSOs are positioned to provide efficiently at scale.
The retina segment specifically benefits from strong demographic tailwinds. An aging population is driving sustained demand for age-related macular degeneration, diabetic retinopathy and other retinal disease treatments, several of which involve high-cost injectable biologics for which procurement relationships with distributors carry meaningful economic value. For Cencora, consolidating physician networks around RCA deepens those procurement relationships while generating management fee revenue and clinical research income. The EyeSouth acquisition adds physician density and geographic coverage to a platform already structured to absorb bolt-on additions without significant integration risk.
Financial and Competitive Implications
At a $1.1Bn valuation, the EyeSouth retina transaction is modest relative to Cencora’s overall scale. Cencora reports annual revenues in excess of $300Bn and currently ranks tenth on the Fortune 500. While the deal’s near-term financial contribution is incremental — with management’s guidance of slight EPS accretion reflecting its “bolt-on” nature — the competitive implications are more significant. Each physician practice brought into the RCA network represents a long-term procurement and service relationship that strengthens Cencora’s position in ophthalmology against rival distributors and independent MSOs.
The transaction also reinforces Cencora’s positioning as a vertically integrated healthcare services company rather than a pure pharmaceutical distributor. That repositioning has been a deliberate strategic objective and carries valuation implications, as specialty services businesses typically command higher multiples than distribution operations. The continued expansion of RCA through targeted acquisitions is consistent with that objective and signals that Cencora views ophthalmology as a long-term platform rather than a one-time investment.
About DelMorgan & Co. (www.delmorganco.com)
With over $300 billion of successful transactions in over 80 countries, DelMorgan‘s Investment Banking professionals have worked on some of the most challenging, most rewarding and highest profile transactions in the U.S. and around the globe. DelMorgan specializes in capital raising and M&A advisor services for companies across all industries and is recognized as one of the leading investment banking practices in California and globally.
Learn more about DelMorgan’s Capabilities, Transactions, and why DelMorgan is ranked as the #1 Investment Bank in Los Angeles and #2 in California by Axial.
